Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

November 3, 2021

Wellinks secures $25M in new funding for virtual COPD product

A look at Wellinks' user interface.
By Liese Klein

New Haven-based digital healthcare firm Wellinks closed a Series C $25 million funding round, the company announced Wednesday.

The cash infusion will fund clinical research and development for the company’s virtual Chronic Obstructive Pulmonary Disease (COPD) management product, Wellinks said in a statement. 

New investor Morningside Ventures led the round, which included returning investors HighCape Capital, Connecticut Innovations, Benslie Ltd. and Stonehenge Capital.

PHOTO | CONTRIBUTED
Alex Waldron

CEO Alex Waldron said, “At Wellinks, we are combining evidence-based care and technology into a virtual-first solution that prioritizes the individual experience, meets the patient where they are and empowers them to take control of their COPD.”

The Wellinks product combines virtual pulmonary rehab, health coaching and monitoring through connected devices and a patient-friendly app. It is designed to integrate with existing care plans.

Formed in 2019 through a merger with Convexity Scientific Inc., Wellinks brought in $14 million through a Series B funding round led by HighCape in 2019. 

Contact Liese Klein at lklein@newhavenbiz.com.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF